Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data.

In the analysis, brigatinib monotherapy showed a trend toward lower mortality risk compared with alectinib monotherapy; however, this difference was not statistically significant in the multivariable analysis (HR, 0.69; 95% CI: 0.46–1.03; P=0.07).

also in 53,322 other papers

These findings suggest that alectinib was associated with longer PFS, whereas brigatinib showed a nonsignificant trend toward improved OS, although this advantage was attenuated after multivariable adjustment.

also in 5,406 other papers